FDA HALCION REVIEW IS EXAMINING AT LEAST TWO NEW ALLEGATIONS
Executive Summary
FDA HALCION REVIEW IS EXAMINING AT LEAST TWO NEW ALLEGATIONS raised in an investigative report that resulted from a December 1991-March 1992 inspection of Upjohn's facilities. The agency said it will evaluate the entire report but focus on what information appears to be new, such as allegations from the FDA investigators' establishment inspection report (EIR) that Upjohn misrepresented data to gain approval for use of Halcion beyond 14 days and that Upjohn hid from FDA the death of a patient taking Xanax (alprazolam) during clinical development.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth